Pricing
  1. US-listed companies
  2. HALOZYME THERAPEUTICS, INC.
  3. Financials
  4. EBITDA margin (%)

HALOZYME THERAPEUTICS, INC. (HALO)

Market cap
$7.9B
P/E ratio
SummaryFinancials
Period EndEBITDA margin (%) YoY (%)
Dec 31, 202455.3+31.59%
Dec 31, 202342+1.29%
Dec 31, 202241.5-34.02%
Dec 31, 202162.9+14.09%
Dec 31, 202055.1-270.17%
Dec 31, 2019-32.4-26.49%
Dec 31, 2018-44.1-267.74%
Dec 31, 201726.3-147.71%
Dec 31, 2016-55.1+188.62%
Dec 31, 2015-19.1-76.54%
Dec 31, 2014-81.3-43.73%
Dec 31, 2013-144.5+16.42%
Dec 31, 2012-124.1+271.50%
Dec 31, 2011-33.4

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat